Vilya的动态

When the going gets tough, the tough get going. Dominic Esposito and team from the Protein Expression Lab at Frederick National Laboratory for Cancer Research in an heroic effort expressed, purified and sorted out the structure and complex formation of KRAS, RRAS2, and MRAS bound to the catalytic subunit of PI3Kα. Step towards elucidating the PI3K-AKT-mTOR pathway and the cure for cancer. Genes designed and made by your friends at ATUM. https://lnkd.in/g34edwvs

Did you know that cell avidity, a measure of binding strength between cells, can be used to identify CAR-T products that are both potent and safe? Dr. Yufei (Sophie) Wang and Professor Wayne Marasco from Dana Farber Cancer Institute?recently published in Molecular Cancer and identified a highly efficacious anti-CAIX CAR without any concerning OTOT toxicity, resulting in an immunotherapeutic product that can now be specifically and safely applied in the clinic. Find the study here: https://bit.ly/3wpJen4

?? Biomolecules is proud to announce the first paper in our Special Issue, Molecular Advances in Drug Resistance and Novel Therapies for Cancer. ?? Guest Edited by Dr. Agnieszka Wolnicka-Glubisz and Dr. Agnieszka Wolnicka-Glubisz. "RIPK4 Downregulation Reduces ABCG2 Expression, Increasing BRAF-Mutated Melanoma Cell Susceptibility to Cisplatin- and Doxorubicin-Induced Apoptosis" By Bartlomiej Olajossy et al. ?? Read it here: https://lnkd.in/eUJuc6bd ?? Contribute to this important topic! Submit your research by 30 June 2025: https://lnkd.in/eWz2hpFm

In Dr. Antonis Kourtidis' lab, a Ph.D. candidate is exploring RNA to uncover novel biomarkers for colon cancer, with the aim of identifying new therapeutic targets to enhance patient outcomes. Learn more about Dr. Kourtidis’ lab here: https://bit.ly/4fFC7aP

#cancersmdpi ?? New paper alert! Our latest #review explores *Extracellular Vesicle- and Mitochondria-Based Targeting of Non-Small Cell Lung Cancer Response to Radiation*. Dive into the challenges and perspectives in this field. ????By Sergey Leonov et al Yulia Merkher Read it here: https://lnkd.in/dcNVY6DA

A hallmark of cancer refers to a defining characteristic that enables the growth and survival of cancer cells. These include traits like sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, and the ability to metastasize. Understanding these hallmarks is crucial for developing targeted therapies, as they represent the biological mechanisms driving tumor development and progression. Each hallmark highlights specific vulnerabilities that can be exploited for therapeutic intervention, forming the foundation for modern cancer research and treatment strategies.

Preprint Alert!!??Silver nanoparticles (AgNPs) from Selaginella bryopteris (Sb) act as potential cytotoxic agents against ovarian cancer SKOV-3 cell lines (IC50: 7.81 μg/ml) in laboratory setups. Rhamnetin, a Sb phytochemical can also serve as a potential PARP-1 inhinitor. Read this paper from Dr. Neha Kapoor and us co-authors. Happy to be a part of it?? https://lnkd.in/gWsyctJm

The concepts of modern immunogenomics began to evolve from the late 1980s. As a result of the mutations that occur, cancer cells present novel, tumour specific antigens on their surface. These antigens are proteins, carbohydrates, or glycolipids and can be classified as tumour-specific antigens (TSA) and tumour-associated antigens (TAA).

Thrilled to share our latest review @NatureRevCancer on "Decoding the functional impact of the cancer genome through protein–protein interactions (PPIs)" that summarizes how oncogenic mutations impact PPIs, technologies for monitoring PPIs, and their therapeutic implications. It is based on exciting publications of many outstanding investigators-thank you! https://lnkd.in/dCaksbik Emory University School of Medicine Winship Cancer Institute of Emory University Emory University https://rdcu.be/d6bn5

Did you see our WRN PCC Nomination announcement today? Check out this new paper that was published today (not our paper) and is very relevant to WRN. The paper provides mechanistic insights into the role of WRN in DNA end resection and homologous recombination, particularly in the context of BRCA1-BARD1's enhancement of WRN's helicase activity. It does not explicitly advocate for WRN inhibition as a therapeutic strategy for cancer. But it focuses on how WRN, together with BRCA1-BARD1, CtIP, and MRN complexes, contributes to DNA repair processes. https://lnkd.in/gRhMj_YT